Icon acquires Mapi Group, ups financial guidances

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Kritchanut)
(Image: iStock/Kritchanut)
Icon plc is expanding its commercialization offerings through its has acquisition of Mapi Group, a global research company.

The Mapi Group was founded in 1974 and provides real-world evidence, strategic regulatory services, pharmacovigilance, market access, and language services to support commercialization.

Through the acquisition, Icon will also have access to Mapi Research Trust, a non-profit that provides outcomes research globally.

Per the company’s website, the Trust features more than 4,000 clinical outcomes assessments (COA), more than 40,000 COA translations, and a research library with more than 29,000 COAs.

Dr. Steve Cutler, Icon CEO commented in the press release: “Our customers will also benefit from ICON’s access to the industry’s broadest set of COA tools and instruments as well as new and enhanced real world data set​s.”

Following the acquisition, Icon has increased its earnings and revenue guidances.

According to the company’s earnings results, also published today, the earnings guidance has been increased from a range of $5.06 - $5.26bn to $5.18 - $5.38bn. Revenue guidance increased from a range of $1.70 - $1.75bn to $1.74 - $1.77bn.

Icon reported gross business wins of $649m in the second quarter and cancelations of $86m, which resulted in net business wins of $563 million and a net book to bill of 1.31.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars